Fatigue in cancer patients receiving chemotherapy: an analysis of published studies.

Fatigue is a subjective experience that affects everybody. In healthy individuals, it can be considered a physiological response to physical or psychological stress. In people with specific diseases, however, fatigue often represents one of the most significant problems. Fatigue can be caused by many factors, both intrinsic to the patient and extrinsic, such as therapeutic interventions. This review, based on published studies, has been conducted with the aim of presenting a critical discussion of the available information on the characteristics, causes and potential treatments of fatigue in cancer patients receiving chemotherapy. The incidence of fatigue in these patients, the methods for measuring and evaluating fatigue, and possible therapeutic options are discussed. An appraisal of the toxicity of various chemotherapeutic agents is also presented. Although fatigue is now an ever more considered aspect of the toxicity of chemotherapy, it remains difficult to establish what standard should be used to make a quali-quantitative evaluation of this symptom. Furthermore, in the absence of a clear demonstration of the efficacy of some therapies, the management of cancer-related fatigue remains poorly defined (except for the treatment of anemia-related fatigue). New randomized clinical trials are necessary to indicate the best strategies for tackling this important problem.

[1]  K. Dalhoff,et al.  Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. , 2001, European journal of cancer.

[2]  B. Scheithauer,et al.  A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas , 2000, Investigational New Drugs.

[3]  M. Gore,et al.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[5]  M. Kris,et al.  Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Greil,et al.  The impact of hemoglobin levels on fatigue and quality of life in cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Friedlander,et al.  Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Hainsworth,et al.  Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Pignon,et al.  A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Jacobsen,et al.  Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? , 1999, Cancer control : journal of the Moffitt Cancer Center.

[11]  S. Barni,et al.  Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  E. Frei,et al.  Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloretjyl)-1-nitrosourea (BCNU). , 1974, Annals of surgery.

[13]  P. Jacobsen,et al.  A multidimensional measure of fatigue for use with cancer patients. , 1998, Cancer practice.

[14]  M. Dodd,et al.  Patients' perspectives of fatigue while undergoing chemotherapy. , 1997, Oncology nursing forum.

[15]  M. Mori,et al.  Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. , 2001, Medicine and science in sports and exercise.

[16]  John A Thompson,et al.  Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. , 2002, Oncology nursing forum.

[17]  D. Cella,et al.  Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. , 1997, Seminars in hematology.

[18]  N. Malamos,et al.  Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. , 2001, European journal of cancer.

[19]  R. Schilsky,et al.  First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Muir,et al.  Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Richardson,et al.  Fatigue: a concept analysis. , 1996, International Journal of Nursing Studies.

[22]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Shin,et al.  Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Aistars Fatigue in the cancer patient: a conceptual approach to a clinical problem. , 1987, Oncology nursing forum.

[25]  S. Closs,et al.  Side effects expected and experienced by women receiving chemotherapy for breast cancer. , 1991, BMJ.

[26]  D. Nerenz,et al.  Factors contributing to emotional distress during cancer chemotherapy , 1982, Cancer.

[27]  Kathleen M. Fairfield,et al.  Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. , 1998, Archives of internal medicine.

[28]  J. Hainsworth,et al.  Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Schilsky,et al.  Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Rossi,et al.  Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. , 1997, European journal of cancer.

[31]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Winningham Walking program for people with cancer. Getting started. , 1991, Cancer nursing.

[35]  F. Dimeo,et al.  Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy , 1999, Cancer.

[36]  J. Groopman,et al.  Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.

[37]  S. Pickard-Holley Fatigue in cancer patients: A descriptive study , 1991, Cancer nursing.

[38]  I. Vlachonikolis,et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.

[39]  J. Carmichael,et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Ducreux,et al.  Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  V. Mock Fatigue management , 2001, Cancer.

[42]  H. Keizer,et al.  Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  L. Nail,et al.  Fatigue and the cancer experience: the state of the knowledge. , 1994, Oncology nursing forum.

[44]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Bogaerts,et al.  Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Hutchins,et al.  Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Rosso,et al.  Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  K. Blesch,et al.  Correlates of fatigue in people with breast or lung cancer. , 1991, Oncology nursing forum.

[50]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Hainsworth,et al.  Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma , 2002 .

[52]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[53]  S. Horning,et al.  Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. , 2000, The oncologist.

[54]  E. Smets,et al.  The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. , 1995, Journal of psychosomatic research.

[55]  Mellar P. Davis,et al.  Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study , 2001, The American journal of hospice & palliative care.

[56]  L. Fallowfield,et al.  Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy , 2002, British Journal of Cancer.

[57]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Nixon,et al.  Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Gregor,et al.  Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  H. Burger,et al.  Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  S. Barni,et al.  Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  J. Nortier,et al.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Ozols,et al.  Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  S. Lippman,et al.  Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma , 2001, Cancer.

[65]  Cancer-related fatigue: guidelines for evaluation and management. , 1999 .

[66]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Zucchetti,et al.  Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  S. Cha,et al.  Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  D. Cella,et al.  The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.

[70]  Terry L. Smith,et al.  Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Kugler,et al.  Phase II trials of 5‐fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma , 1996, Cancer.

[72]  J. Glaspy Anemia and fatigue in cancer patients , 2001, Cancer.

[73]  C. Cleeland,et al.  The rapid assessment of fatigue severity in cancer patients , 1999, Cancer.